- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Celldex Halts Eczema Drug Development After Mid-Stage Trial Failure

Bengaluru: Celldex Therapeutics said on Thursday it would stop developing its experimental drug for eczema after the treatment failed to meet the main and key secondary goals of a mid-stage study.
The study enrolled 131 patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition commonly known as eczema.
The drug, barzolvolimab, did not significantly reduce itching after 16 weeks and showed no meaningful improvement over placebo on other key measures.
The drug reduced mast cells, immune cells involved in allergic and inflammatory reactions, but the results suggest they are not the main driver of atopic dermatitis, the company said.
Celldex said the limited improvements fell short of its threshold for further development, with no added benefit after 32 weeks
The treatment was well tolerated, with a safety profile consistent with earlier studies.
Celldex will continue late-stage studies of barzolvolimab in three hive-related skin conditions: chronic spontaneous urticaria, cold urticaria and symptomatic dermographism.
The company plans to seek US approval for the drug in chronic spontaneous urticaria in 2027 and announce additional indications by year-end.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

